Predicting outcomes in rheumatoid arthritis related interstitial lung disease.

The aim of this study was to compare radiology-based prediction models in rheumatoid arthritis-related interstitial lung disease (RAILD) to identify patients with a progressive fibrosis phenotype.RAILD patients had computed tomography (CT) scans scored visually and using CALIPER and forced vital capacity (FVC) measurements. Outcomes were evaluated using three techniques, as follows. 1) Scleroderma system evaluating visual interstitial lung disease extent and FVC values; 2) Fleischner Society idiopathic pulmonary fibrosis (IPF) diagnostic guidelines applied to RAILD; and 3) CALIPER scores of vessel-related structures (VRS). Outcomes were compared to IPF patients.On univariable Cox analysis, all three staging systems strongly predicted outcome (scleroderma system hazard ratio (HR) 3.78, p=9×10

Informations de copyright

Copyright ©ERS 2019.

Déclaration de conflit d'intérêts

Conflict of interest: J. Jacob reports advisory board fees from Boehringer Ingelheim, outside the submitted work. Conflict of interest: N. Hirani reports personal fees from Boehringer Ingelheim, Intermune, Roche, Galecto and UCB, outside the submitted work. Conflict of interest: C.H.M. van Moorsel has nothing to disclose. Conflict of interest: S. Rajagopalan reports grants (provided to Mayo Clinic for supporting the handling and processing of the CT datasets used in the study) from Royal Brompton Hospital, during the conduct of the study; and that Mayo Clinic has received royalties from Imbio, LCC towards licensing CALIPER, outside the submitted work; in addition, S. Rajagopalan has a patent Systems And Methods For Analysing In Vivo Tissue Volumes Using Medical Imaging Data licensed to Imbio, LLC. Conflict of interest: J.T. Murchison has nothing to disclose. Conflict of interest: H.W. van Es has nothing to disclose. Conflict of interest: B.J. Bartholmai reports grants (provided to Mayo Clinic for supporting the handling and processing of CT datasets used in the study) from Royal Brompton Hospital, during the conduct of the study; and that Mayo Clinic has received royalties from Imbio, LCC towards licensing CALIPER, outside the submitted work; in addition, B.J. Bartholmai has a patent Systems And Methods For Analysing In Vivo Tissue Volumes Using Medical Imaging Data licensed to Imbio, LLC. Conflict of interest: F.T. van Beek has nothing to disclose. Conflict of interest: M.H.L. Struik has nothing to disclose. Conflict of interest: G.A. Stewart has nothing to disclose. Conflict of interest: M. Kokosi has nothing to disclose. Conflict of interest: R. Egashira has nothing to disclose. Conflict of interest: A.L. Brun has nothing to disclose. Conflict of interest: G. Cross has nothing to disclose. Conflict of interest: J. Barnett has nothing to disclose. Conflict of interest: A. Devaraj reports personal fees from Roche and Boehringer Ingelheim, outside the submitted work. Conflict of interest: G. Margaritopoulos has nothing to disclose. Conflict of interest: R. Karwoski reports grants (provided to Mayo Clinic for supporting the handling and processing of CT datasets used in the study) from Royal Brompton Hospital, during the conduct of the study; and that Mayo Clinic has received royalties from Imbio, LCC towards licensing CALIPER, outside the submitted work; in addition, R. Karwoski has a patent Systems And Methods For Analysing In Vivo Tissue Volumes Using Medical Imaging Data licensed to Imbio, LLC. Conflict of interest: E. Renzoni reports lecture fees from Roche and Takeda, and lecture fees and advisory board fees from Boehringer, outside the submitted work. Conflict of interest: T.M. Maher has, via his institution, received industry-academic funding from GlaxoSmithKline R&D, UCB and Novartis and has received consultancy or speakers fees from Apellis, Astra Zeneca, Bayer, Biogen Idec, Boehringer Ingelheim, Cipla, GlaxoSmithKline R&D, Lanthio, InterMune, ProMetic, Roche, Sanofi-Aventis, Takeda and UCB. Conflict of interest: A.U. Wells reports advisory board and speaker fees from Intermune, Boehringer Ingelheim, Roche and Bayer, advisory board fees from Gilead and MSD, and speaker fees from Chiesi, outside the submitted work.